Syngene International, a subsidiary of Biocon, the Indian biotechnology major and Endo Pharmaceuticals have signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer. Syngene and Endo will partner on two new discovery programmes, strengthening their ongoing alliance in cancer research. Under the agreement, Endo will retain all the rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.
Thus, through the extended partnership, Syngene International and Endo Pharma will leverage their complementary and synergistic capabilities towards innovating novel therapeutic molecules for a robust cancer pipeline.
Syngene is India’s leading contract organization offering integrated drug and development service with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, customs synthetics, process R&D and formulation development for small and large molecules.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.05 |
Dr. Reddys Lab | 1274.25 |
Cipla | 1553.20 |
Lupin | 2184.00 |
Zydus Lifesciences | 1001.85 |
View more.. |